Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study

References

• Endo A. The origin of the statins. Atheroscler Suppl. 2004;5:125–130.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators, Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
   PubMed Web of Science ®Google Scholar
• Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23:317–324.
   PubMed Web of Science ®Google Scholar
• Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581–585.
   PubMed Web of Science ®Google Scholar
• Mohaupt MG, Karas RH, Babiychuk EB, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009;181:E8–E11.
   Google Scholar
• Tiwari A, Bansal V, Chugh A, et al. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf. 2006;5:651–666.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–2934.
   PubMed Web of Science ®Google Scholar
• Sung JC, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care. 1998;4:1421–1430.
   PubMed Web of Science ®Google Scholar
• Goodman LA. Snowball sampling. Ann Math Stat. 1961;32:148–170.
   Google Scholar
• Pasternak RC, Smith SC, Bairey-Merz CN, et al. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI. Clinical Advisory on the use and safety of statins. Circulation. 2002;106:1024–1028.
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice; European Association for Cardiovascular Prevention and Rehabilitation. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis. 2012;223:1–68.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–414.
   PubMed Web of Science ®Google Scholar
• Cohen JD, Brinton EA, Ito MK, et al. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208–215.
   PubMed Web of Science ®Google Scholar
• Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96–103.
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408–416.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007;49:1753–1762.
   PubMed Web of Science ®Google Scholar
• Silva M, Matthews ML, Jarvis C, et al. Metaanalysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29:253–260.
   PubMed Web of Science ®Google Scholar
• Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10:373–387.
   PubMed Web of Science ®Google Scholar
• Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol. 2012;159:169–176.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs. 2010;11:323–332.
   PubMed Web of Science ®Google Scholar
• Rowan CG, Brunelli SM, Munson J, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012;21:494–506.
   PubMed Web of Science ®Google Scholar
• Ming EE, Davidson MH, Gandhi SK, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol. 2008;2:453–463.
   PubMed Web of Science ®Google Scholar
• Sauret JM, Marinides G, Wang GK. Rhabdomyolysis. Am Fam Physician. 2002;65:907–912.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395–2410.
   PubMed Web of Science ®Google Scholar
• Hoffman KB, Kraus C, Dimbil M, et al. A survey of the FDA’s AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One. 2012;7:e42866.
   Google Scholar
• Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6:390–399.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Honda T, Yokoya S, et al. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. Faseb J. 2007;21:4087–4094.
   PubMed Web of Science ®Google Scholar